Operating
Stock-Based Comp
ResMed Stock-Based Comp decreased by 7.4% to $26.79M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.1%, from $24.12M to $26.79M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 9.4% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.90M | $17.30M | $16.10M | $15.86M | $15.99M | $16.92M | $16.46M | $17.83M | $19.93M | $18.51M | $19.84M | $20.44M | $21.39M | $20.16M | $22.63M | $24.12M | $24.75M | $21.16M | $28.94M | $26.79M |
| QoQ Change | — | +2.4% | -6.9% | -1.5% | +0.8% | +5.8% | -2.7% | +8.3% | +11.7% | -7.1% | +7.2% | +3.0% | +4.6% | -5.8% | +12.3% | +6.6% | +2.6% | -14.5% | +36.8% | -7.4% |
| YoY Change | — | — | — | — | -5.3% | -2.2% | +2.3% | +12.4% | +24.6% | +9.4% | +20.5% | +14.6% | +7.4% | +8.9% | +14.1% | +18.0% | +15.7% | +5.0% | +27.9% | +11.1% |
Range$15.86M – $28.94M
CAGR+10.2%
Avg YoY Growth+11.5%
Median YoY Growth+11.8%
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is ResMed's stock-based comp?
- ResMed (RMD) reported stock-based comp of $26.79M in Q1 2026.
- How has ResMed's stock-based comp changed year-over-year?
- ResMed's stock-based comp increased by 11.1% year-over-year, from $24.12M to $26.79M.
- What is the long-term trend for ResMed's stock-based comp?
- Over 4 years (2021 to 2025), ResMed's stock-based comp has grown at a 9.4% compound annual growth rate (CAGR), from $63.93M to $91.66M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.